Hu Dong, Yang Xiaokang, Wu Jing, Wang Ganxun, Wang Wenyang, Qi Zhenyu, Chen Gong, Zhang Rongbo
Institute of Infection and Immunology, Department of Immunology, Medical School, Anhui University of Science and Technology, Huainan 232001, China.
Deparment of Pathology, General Hospital of Oriental Group, Huainan 232001, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Jun;30(6):581-4.
To construct an autophagy-targeted vaccine harboring the genes encoding lipoprotein antigen precursor LpqH from Mycobacterium tuberculosis and microtubule-associated protein light chain-3(LC3), and to investigate its efficacy of inducing and targeting autophagy.
The expressions of LC-3 and LC3-LpqH in RAW264.7 cells were detected by Western blotting after transfected with pCMV-LpqH and pCMV-LC3-LpqH plasmids respectively. The pCMV-LC3-LpqH or pCMV-LpqH plasmids were transfected into GFP-LC3-RAW264.7 cells to analyze the localization of LC3-LpqH by immunofluorescence staining.
After transfected with pCMV-LpqH DNA, RAW264.7 cells showed a significant increase of LC-3 amount. The LC3-LpqH fusion protein was also detected in RAW264.7 cells after pCMV-LC3-LpqH transfection and in a dose-dependent manner. Interestingly, LpqH was found to be transported to autophagosomes through the fusion protein, which was demonstrated by the co-localization of GFP-LC3 and LC3-LpqH on autophagosomes.
The recombinant plasmid encoding pCMV-LC3-LpqH could enhance the autophagy in vitro, and facilitate the localization of LpqH on autophagosomes. Our study provides a new practical strategy for the development of improved vaccines against Mycobacterium tuberculosis.
构建一种携带编码结核分枝杆菌脂蛋白抗原前体LpqH和微管相关蛋白轻链3(LC3)基因的自噬靶向疫苗,并研究其诱导和靶向自噬的效果。
分别用pCMV-LpqH和pCMV-LC3-LpqH质粒转染RAW264.7细胞后,通过蛋白质免疫印迹法检测LC-3和LC3-LpqH的表达。将pCMV-LC3-LpqH或pCMV-LpqH质粒转染到GFP-LC3-RAW264.7细胞中,通过免疫荧光染色分析LC3-LpqH的定位。
用pCMV-LpqH DNA转染后,RAW264.7细胞中LC-3的含量显著增加。pCMV-LC3-LpqH转染RAW264.7细胞后也检测到LC3-LpqH融合蛋白,且呈剂量依赖性。有趣的是,通过融合蛋白发现LpqH被转运到自噬体,这通过GFP-LC3和LC3-LpqH在自噬体上的共定位得以证明。
编码pCMV-LC3-LpqH的重组质粒可在体外增强自噬,并促进LpqH在自噬体上的定位。我们的研究为开发改良的抗结核分枝杆菌疫苗提供了一种新的实用策略。